Mouwasat Medical Services Company (4002) Q2 2026 earnings summary

Executive summary

• Revenue for the six months ended 30 June 2026 reached SR 1.71 billion, up from SR 1.56 billion year-over-year, driven by growth in both medical services and pharmaceutical sales.

• Net profit attributable to shareholders for the six-month period was SR 412.4 million, compared to SR 384.0 million in the prior year.

• The Yanbu hospital commenced operations in February 2026, transferring SR 407.9 million from construction in progress to property and equipment.

Financial highlights

• Gross profit for the six-month period was SR 699.4 million, up from SR 674.8 million year-over-year.

• Basic and diluted EPS for the six months was SR 2.06, compared to SR 1.92 in the prior year.

• Total assets increased to SR 6.62 billion as of 30 June 2026, from SR 5.99 billion at year-end 2025.

• Cash and cash equivalents at period end were SR 159.0 million, down from SR 497.5 million at year-end 2025.

• Dividends of SR 225 million were paid to shareholders during the period.

Outlook and guidance

• The Group is assessing the impact of IFRS 18, which will affect the structure of the statement of profit or loss starting 2027.

• Capital commitments for expansion projects total SR 370.87 million as of 30 June 2026.